For decades, scientists believed they understood what caused the dangerous inflammation associated with a rare genetic disorder. Now, researchers at the Garvan Institute of Medical Research have uncovered evidence that challenges 30 years of established thinking and could open the door to a new treatment.
The condition, known as mevalonate kinase deficiency (MKD), can cause severe inflammatory episodes that are sometimes life-threatening. A new study published in Immunity identifies a previously underrecognized problem involving natural killer (NK) cells, immune cells that normally help the body eliminate infected cells.
The researchers found that these cells malfunction in people with MKD, setting off an excessive inflammatory response when infections occur. The discovery also points to a possible treatment using existing medications called JAK inhibitors, which could be particularly valuable for patients who do not respond to current therapies.
“This study has revealed a new target for this inflammatory disorder and sets the scene for future clinical studies to explore the use of JAK inhibitors or other drugs to neutralize interferon gamma in patients with MKD,” says Professor Mike Rogers, Lab Head at Garvan and senior author of the study. “This could lead to a targeted treatment that hasn’t been tried before.”
Why a Rare Immune Disease Causes Dangerous Inflammation
MKD is a lifelong condition known to affect hundreds of children and adults around the world, although researchers suspect that many people with the disorder have never been diagnosed. Patients experience recurring attacks of high fever, skin rashes, joint pain, and inflammation in the abdomen. The most serious episodes can cause potentially fatal complications.
For roughly three decades, research into the disease has largely centered on macrophages, immune cells that help coordinate the body’s inflammatory defenses. Existing treatments are designed to block an inflammatory signal released by these cells. However, approximately half of patients do not respond adequately, leaving a major need for better treatment options.
To investigate what might be missing from the prevailing explanation, the Garvan team examined blood samples from people with MKD and studied preclinical models of the disorder.
Their experiments revealed a significant defect in natural killer cells, which play an important role in the body’s early defenses against viral infections. In MKD, these cells fail to mature properly and struggle to perform one of their most important functions: destroying infected cells before an infection can spread.
The consequences go beyond an impaired ability to fight infection. When natural killer cells cannot eliminate their targets, they release large amounts of inflammatory signaling molecules, activating other parts of the immune system and potentially triggering widespread inflammation.
“We found that these immune cells are essentially misfiring,” explains Professor Rogers. “NK cells are loaded with toxic ammunition, stored in granules that are released to kill infected cells. However, in MKD these toxic granules can’t be released from NK cells and remain trapped inside. When an NK cell fails to kill its target, it compensates by shouting for help, pumping out large amounts of interferon gamma – a powerful inflammatory signal. This activates other immune cells and causes the dangerous fever and widespread inflammation seen in patients.”
Discovery Challenges 30 Years of Immune Disease Research
The findings suggest that natural killer cell dysfunction, rather than macrophage activity alone, plays a central role in driving MKD.
Dr. Marcia Munoz, Group Leader in the Rogers Lab and lead researcher on the study, says the results represent a major change in how scientists understand the disease.
“This really turns on its head 30 years of dogma about what was thought to be the underlying mechanism of disease. In MKD, the primary problem is in NK cells and not in macrophages, as previously believed,” she says.
To investigate how this cellular defect contributes to the disorder, the Garvan researchers collaborated with Professor Mariapia Degli-Esposti and scientists at Monash University.
Using preclinical models, the team established a connection between malfunctioning natural killer cells and the severe symptoms associated with MKD. Their experiments showed that when the immune system cannot clear a viral infection, the resulting inflammatory response can cause extensive damage to organs.
These results help explain why a disorder involving defective immune defenses can also produce episodes of extreme inflammation.
Existing Drug Shows Promise for a New Treatment
The discovery has already helped guide an experimental treatment approach for a severely affected infant.
Working with doctors at the Royal Children’s Hospital in Melbourne, the researchers explored whether baricitinib could reduce the excessive inflammatory signaling associated with MKD.
Baricitinib belongs to a class of medications known as JAK inhibitors. These drugs interfere with signaling pathways used by the immune system, including those involved in responses to interferon gamma. The medication is already used to treat other immune-related conditions, including rheumatoid arthritis and eczema.
Doctors added baricitinib to the infant’s existing treatment regimen and subsequently observed an improvement in the child’s condition. Inflammatory flare-ups became less frequent, and severe inflammation affecting the gastrointestinal tract began to heal.
Although the results from a single patient cannot establish whether the treatment will work more broadly, the improvement provides encouraging early evidence for a strategy that targets a different part of the inflammatory process.
The researchers believe their findings provide a foundation for future clinical studies investigating JAK inhibitors and other medications that block interferon gamma activity in patients with MKD, particularly those who have not benefited from standard treatments.
Discovery Could Help Explain Other Genetic Diseases
The potential implications extend beyond MKD itself.
Researchers have introduced the term ‘prenylopathies’ to describe a family of genetic disorders involving the same metabolic pathway affected in MKD. Early findings suggest that these related diseases may share a similar underlying problem involving natural killer cells that fail to function properly and instead generate excessive inflammatory signals.
If further studies confirm this connection, scientists may be able to identify common disease mechanisms and develop more targeted approaches to diagnosis and treatment across multiple disorders.
“Confirming this link could help end the diagnostic odyssey many patients endure for years or even decades before receiving effective treatment,” says Professor Rogers.
Professor Mike Rogers is a Conjoint Professor at St Vincent’s Clinical School, Faculty of Medicine and Health, UNSW Sydney. Dr. Marcia Munoz is a Conjoint Senior Lecturer at St Vincent’s Clinical School, Faculty of Medicine and Health, UNSW Sydney.
